In a press conference on a cost and other related questions about safety, approval and efficacy of a Covid-19 vaccine said that the vaccine is 200 percent safe and company is already conducting trials in 12 countries, “Approval of COVAXIN for emergency use is a giant leap for innovation & novel product development in India. It is a proud moment for the nation & a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India.” said Dr Krishna Ella , Bharat Biotech’s Managing Director
Dr Ella also speak about providing efficacy data in one weeks of time,”Give me one week’s time, I will give you confirm data.”
On being asked about Covaxin vaccine trials on children , he said “Covaxin is a simple two-dose, we are the only vaccine for above 12 years of age right now. We are planning to do even children trials soon, as per the protocol.”
The cost of a COVAXIN is yet to be decided, “In the beginning, the cost of vaccine may be a little higher. As the scale of production increases, the price will be controlled by market.” said Dr.Ella
